Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Improvement of the Inactivated Sars-Cov-2 Vaccine Potency Through Formulation in Alum/Naloxone Adjuvant; Robust T Cell and Anti-Rbd Igg Responses Publisher



Haghighi M1, 2 ; Khorasani A3 ; Karimi P1, 2 ; Mahdavi M1, 2, 4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Advanced Therapy Medicinal Product (ATMP) Department, Breast Cancer Research Center, Motamed Cancer Institute, Academic Center for Education, Culture and Research (ACECR), Tehran, Iran
  2. 2. Recombinant Vaccine Research Center, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of FMD Vaccine Production, Razi Vaccine & Serum Research Institute, Agricultural Research, Education & Extension Organization (AREEO), Karaj, Iran
  4. 4. Immunotherapy Group, The Institute of Pharmaceutical Science (TIPS), Tehran University of Medical Science, Tehran, Iran

Source: Iranian Journal of Basic Medical Sciences Published:2022


Abstract

Objective(s): SARS-CoV-2, emerging as a major threat to public health, has to be controlled through vaccination. Naloxone (NLX), an opioid receptor antagonist, demonstrated its adjuvant activity for microbial vaccines. In this study, inactivated SARS-CoV-2 was developed in the Alum/NLX adjuvant to increase the potency of the inactivated SARS-CoV-2 vaccine. Materials and Methods: BALB/c mice were immunized on days 0 and 14 with inactivated SARS-CoV-2-Alum, -Alum + NLX 3 mg/kg, -Alum + NLX 10 mg/kg, and -Freund adjuvant, as well as PBS. IFN-γ and IL-4 cytokines and Granzyme-B release were assessed with ELISA. In addition, specific total IgG, IgG1/IgG2a isotypes, and ratio as well as anti-RBD IgG responses were assessed with an optimized ELISA. Results: SARS-CoV-2-Alum-NLX10 group showed a significant increase in the IFN-γ cytokine response versus SARS-CoV-2-Alum, SARS-CoV-2-Alum-NLX3, and PBS groups. The SARS-CoV-2-Alum-NLX3 group exhibited a significant decrease in IL-4 cytokine versus SARS-CoV-2-Alum. The mice immunized with SARS-CoV-2-Alum-NLX10 showed a significant increase in CTL activity versus SARS-CoV-2-Alum and PBS. In addition, mice immunized with SARS-CoV-2-Alum-NLX3, SARS-CoV-2-Alum-NLX10 and SARS-CoV-2-Freund demonstrated an increase in IgG response, as compared with SARS-CoV-2-Alum and PBS group. Furthermore, all formulations of SARS-CoV-2 vaccines could induce both IgG1 and IgG2a isotypes. But, the IgG2a/IgG1 ratio in SARS-CoV-2-Freund and SARS-CoV-2-Alum-NLX10 revealed an increase as compared with that of the SARS-CoV-2-Alum group. Anti-RBD IgG response in the SARS-CoV-2-Alum-NLX10 group showed a significant increase as compared with the Alum-based vaccine. Conclusion: Formulation of inactivated SARS-CoV-2 virus in NLX/alum adjuvant improved the potency of humoral and, especially, cellular responses. © 2022 Mashhad University of Medical Sciences. All rights reserved.
Related Docs
View other Related Docs
1. Different Formulations of Inactivated Sars-Cov-2 Vaccine Candidates in Human Compatible Adjuvants: Potency Studies in Mice Showed Different Platforms of Immune Responses, Viral Immunology (2022)
2. Formulation of a Recombinant Hiv-1 Polytope Candidate Vaccine With Naloxone/Alum Mixture: Induction of Multi-Cytokine Responses With a Higher Regulatory Mechanism, APMIS (2021)
3. Nanoadjuvants Produced by Advanced Nanochelating Technology in the Inactivated-Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine Formulation: Preliminary Results on Cytokines and Igg Responses, Viral Immunology (2023)
4. A Survey on the Adjuvant Role of Naloxone Alone or Combined With Alum in Vaccination Against Fasciolosis in Balb/C Mice, Acta Parasitologica (2019)
5. Increasing of Methicillin-Resistant Staphylococcus Aureus Vaccine Potency, Using a Mixture of Alum-Naloxone: Augmentation of Humoral Immune Responses, Journal of Applied Biological Sciences (2015)
6. Administration of Naloxone in Combination With Recombinant Plasmodium Vivax Ama-1 in Balb/C Mice Induces Mixed Th1/Th2 Immune Responses, Parasite Immunology (2015)
7. Immune Responses of Mice Immunized With Hbsag Formulated in Naloxone/Alum Mixture: Comparison to Fendrix Vaccine, Hepatitis Monthly (2017)
8. Opioids and Viral Infections: A Double-Edged Sword, Frontiers in Microbiology (2016)
Experts (# of related papers)
View all Related Experts
Mohammad Hossein Yazdi (5)
Fazel Shokri (3)
Other Related Docs
9. Evaluation of the Alum–Naloxone Adjuvant Activity Against Experimental Murine Leishmaniasis Due to L. Major, Journal of Parasitic Diseases (2016)
10. Ascorbic Acid and Α-Tocopherol in the Inactivated Sars-Cov-2 Vaccine Formulation: Induction of the Th1 Pattern in Aged Mice, Viral Immunology (2024)
11. Inactivated Herpes Simplex Virus-1 Vaccine Formulated in Aqueous and Alcoholic Extracts of Propolis Boosts Cellular and Igg Responses, Iranian Journal of Basic Medical Sciences (2024)
12. Naloxone Effects Against Cutaneous Leishmaniasis Caused by Leishmania Major Strain Mrho/Ir/75/Er in the Balb/C Mice, Infectious Disorders - Drug Targets (2023)
13. Protective Effect of Pilin Protein With Alum+Naloxone Adjuvant Against Acute Pulmonary Pseudomonas Aeruginosa Infection, Biologicals (2016)
14. Blocking of Opioid Receptors in Experimental Formaline-Inactivated Respiratory Syncytial Virus (Fi-Rsv) Immunopathogenesis: From Beneficial to Harmful Impacts, Medical Microbiology and Immunology (2018)
15. The Effectiveness of Covid-19 Vaccines in Reducing the Incidence, Hospitalization, and Mortality From Covid-19: A Systematic Review and Meta-Analysis, Frontiers in Public Health (2022)
16. Formulation of Recombinant H1n1 Hemagglutinin in Mf59 and Alum Adjuvants: A Comparison of the Vaccines Potency and Efficacy in Balb/C Mice, Viral Immunology (2023)
17. Immunologic Balance of Regulatory T Cell/T Helper 17 Responses in Gastrointestinal Infectious Diseases: Role of Mirnas, Microbial Pathogenesis (2019)
18. Immunogenic Potential of Biogenic Vs. Synthetic Selenium Nanoparticles in Vaccine Candidate Against Methicillin-Resistant Staphylococcus Aureus, Vaccine: X (2025)
19. Evaluation of Seroconversion Rate Following Sars Cov 2 Vaccination in Health Care Workers at Shahid Beheshti University of Medical Sciences, Avicenna Journal of Medical Biotechnology (2023)
20. All About Covid-19 in Brief, New Microbes and New Infections (2020)
21. Vaccine Design and Delivery Approaches for Covid-19, International Immunopharmacology (2021)
22. Adjuvant Effects of Pseudomonas Aeruginosa Flagellin on the Immunological Patterns of the Hiv-1 Vaccine Candidate: Vaccine Formulations Versus Different Routes of Immunization, Viral Immunology (2022)
23. Improvement of Hepatitis B Vaccine to Induce Ifn-Γ Cytokine Response: A New Formulation, Microbial Pathogenesis (2021)
24. Recombinant Pbp2a of Methicillin-Resistant S. Aureus Formulation in Alum and Montanide Isa266 Adjuvants Induced Cellular and Humoral Immune Responses With Protection in Balb/C Mice, Microbial Pathogenesis (2020)
25. Safety and Immunogenicity of an Inactivated Virus Particle Vaccine for Sars-Cov-2, Biv1-Coviran: Findings From Double-Blind, Randomised, Placebo-Controlled, Phase I and Ii Clinical Trials Among Healthy Adults, BMJ Open (2022)
26. Glucomannan As a Dietary Supplement for Treatment of Breast Cancer in a Mouse Model, Vaccines (2022)